Testing a new drug combined with chemotherapy for rare bladder cancer

Plain-English translation of NCT06091124 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a new medication called combined with two chemotherapy drugs ( and ) for people with a rare type of bladder cancer called neuroendocrine carcinoma. The medication is given through an IV before patients undergo surgery to remove the bladder. Researchers want to learn whether this combination treatment helps shrink tumors and improves outcomes for patients with this difficult-to-treat cancer.

Neuroendocrine bladder cancer is very rare and aggressive, and standard treatments don't work well for everyone. This trial is testing whether adding a new immunotherapy drug to chemotherapy might help more patients respond to treatment and have better results before surgery.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with invasive neuroendocrine bladder cancer (with the neuroendocrine component making up more than 50% of the tumor)
your cancer is at a stage that can still be surgically removed (T1-T4a, with or without spread to nearby lymph nodes)
you are healthy enough to undergo major bladder surgery, with normal heart, liver, and kidney function
you have not received any prior immunotherapy or other cancer treatments (except intravesical treatments ended at least 1 week before)

You likely don't qualify if…

you have received prior immunotherapy drugs (like anti-PD-1, anti-PD-L1, or anti-CTLA-4 treatments)
you have had radiation therapy to your bladder
you are pregnant, breastfeeding, or unable to use effective contraception for 12 months after treatment
you have HIV, active hepatitis B or C, or active tuberculosis
you have received other cancer treatments or immunotherapy (including steroids) within 4 weeks before starting the study

What participation looks like

You will receive the new medication combined with chemotherapy through an IV every 3 weeks for up to 4 cycles (about 3 months total). During each cycle, you'll visit the hospital for treatment on specific days and have blood tests to monitor your health. After completing the 4 cycles of treatment, you will undergo surgery to remove your bladder, surrounding lymph nodes, and have a urinary diversion procedure created so you can still pass urine. Throughout the study, your doctors will closely monitor how well the treatment is working and watch for any side effects.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(5 sites)

China

Jiangsu Province Hospital, Nanjing, Jiangsu

The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, Shaanxi

RenJi Hospital, Shanghai, Shanghai Municipality

West China Hospital, Chengdu, Sichuan

The Second Hospital of Tianjin Medical University, Tianjin, Tianjin Municipality